10x Genomics Inc. Class A Common Stock (TXG)
Stock · NASDAQ · Industrials
$69.87as of 10/16/2026
Price chart
Active signals
TXG Signal Track Record
How signals performed across all stocks →What TXG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | -2.4% | 46% | October 6, 2026 |
| Bollinger Band Breakout | 24 | +4.3% | 54% | September 15, 2026 |
| Bollinger Band Breakdown | 20 | -1.6% | 50% | March 16, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +7.2% | 75% | October 9, 2025 |
| Any 20-session window (baseline) | +1.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TXG
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromiu…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 1,178
- Website
- www.10xgenomics.com/
Fundamentals
- 1-day range
- $67.52$73.99
- Market cap
- $5.79B
- P/E (trailing)
- —
- P/E (forward)
- 911.18
- EPS (trailing)
- $-0.59
- Dividend yield
- —
- Beta
- 2.00
- Avg. volume
- 3.33M
How 10x Genomics Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
10x Genomics Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- TXG10x Genomics Inc. Class A Common Stock$69.86▼ 3.49%Market cap $5.79BP/E —$11.62$102.81
- BRKRBruker Corporation Common Stock$54.8▼ 3.08%Market cap $7.95BP/E —$32.37$66.98
- AVTRAvantor Inc. Common Stock$16.42▲ 2.05%Market cap $8.91BP/E —$7.27$16.38
- BIOBio-Rad Laboratories Inc. Class A Common Stock$353.7▼ 3.05%Market cap $9.16BP/E 43.88$236.73$396.23
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
- PACBPacific Biosciences of California Inc. Common Stock$1.73▼ 11.73%Market cap $361.85MP/E —$1.07$3.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TXG 10x Genomics Inc. Class A Common Stock | $5.79B | — | $69.86 | ▼ 3.49% | $11.62$102.81 |
| BRKR Bruker Corporation Common Stock | $7.95B | — | $54.8 | ▼ 3.08% | $32.37$66.98 |
| AVTR Avantor Inc. Common Stock | $8.91B | — | $16.42 | ▲ 2.05% | $7.27$16.38 |
| BIO Bio-Rad Laboratories Inc. Class A Common Stock | $9.16B | 43.88 | $353.7 | ▼ 3.05% | $236.73$396.23 |
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
| PACB Pacific Biosciences of California Inc. Common Stock | $361.85M | — | $1.73 | ▼ 11.73% | $1.07$3.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70benzinga · 10/13/2026
- Why Are 10x Genomics (TXG) Shares Soaring TodayYahoo · 10/10/2026
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?Yahoo · 10/9/2026
- 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker ResearchYahoo · 10/8/2026
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood CancersYahoo · 10/7/2026
- Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead BuysYahoo · 10/7/2026
- Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110Benzinga · 10/7/2026
- 10x Genomics Partners With Fred Hutchinson Cancer Center Over Use Of Single Cell, Spatial Technologies In Both Solid Tumor And Hematologic MalignanciesBenzinga · 10/7/2026
Insider Activity
Insider Actions →- Saxonov Serge · September 22, 2026 · Sale2.8K @ $82.37
- Saxonov Serge · September 22, 2026 · Sale9.9K @ $81.83
- Saxonov Serge · September 22, 2026 · Sale9.3K @ $80.9
- Saxonov Serge · September 22, 2026 · Sale2.0K @ $79.62
- Saxonov Serge · September 22, 2026 · Sale1.0K @ $78.23
- Shehnaaz Suliman · September 22, 2026 · Sale1.2K @ $82.28
- Shehnaaz Suliman · September 22, 2026 · Sale2.3K @ $81.67
- Shehnaaz Suliman · September 22, 2026 · Sale1.3K @ $80.82
- Shehnaaz Suliman · September 22, 2026 · Sale614 @ $79.51
- Shehnaaz Suliman · September 22, 2026 · Sale292 @ $78.2
- Taich Adam · September 9, 2026 · Sale13.8K @ $65.26
- Taich Adam · September 9, 2026 · Sale31.4K @ $64.31
- Taich Adam · September 9, 2026 · Sale1.2K @ $63.68
- STUELPNAGEL JOHN R · September 3, 2026 · Sale6.8K @ $62.11
- STUELPNAGEL JOHN R · September 3, 2026 · Sale7.0K @ $60.66
Institutional Ownership
March 31, 2026
- Total shares held
- 117.56M
- Total value held
- $2.45B
- Institutional holders
- 323
- Unknown17.74M
- Unknown11.72M
- Unknown10.08M
- Unknown5.41M
- Unknown5.27M
- Unknown5.11M
- Unknown5.10M
- Unknown4.11M
- Unknown2.90M
- Unknown2.66M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.